Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 202 ...

New York, New York--(Newsfile Corp. - February 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Core Viewpoint - A class action lawsuit has been filed against Beyond Meat, Inc. for allegedly misrepresenting its financial condition, particularly regarding impairment charges related to long-lived assets, which led to significant stock price declines and investor harm [1]. Company Overview - Beyond Meat, headquartered in El Segundo, California, specializes in developing and marketing plant-based meat products under the "Beyond" brand name [1]. Legal Proceedings - The lawsuit pertains to investors who acquired Beyond Meat securities between February 27, 2025, and November 11, 2025, with a deadline for lead plaintiff applications set for March 24, 2026 [1]. - The complaint claims that Beyond Meat failed to disclose that the book value of certain long-lived assets exceeded their fair value, making a material non-cash impairment charge likely [1]. - Following disclosures starting October 24, 2025, Beyond Meat reported $77.4 million in impairment charges, which negatively impacted the company's stock price and harmed investors [1].

NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025 and October 31, 2025, inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHA ...

PYPL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds PayPal (PYPL) Investors of Securities Class Action Deadline on April 20, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses Exceeding $50,000 In PayPal To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in [PayPal] between February 25, 2025 and February 2, 2026 and would like to discuss your legal rig ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against NuScale Power Corporation (NYSE: SMR) and reminds investors of the April 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Allegations Against NuScale - The complaint alleges that NuScale and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose critical information regarding ENTRA1's lack of experience in nuclear power generation [1] - It is claimed that NuScale's commercialization strategy was exposed to material, undisclosed risks of failure, delays, and regulatory challenges due to reliance on ENTRA1 [1] Group 2: Financial Impact - On November 6, 2025, NuScale reported a significant increase in general and administrative expenses, which surged over 3,000% to $519 million from $17 million in the prior year, primarily due to a $495 million payment to ENTRA1 [1] - As a result of this financial disclosure, NuScale's quarterly net loss increased to $532 million, up from $46 million in the previous year [1] Group 3: Stock Performance - Following the financial news, NuScale's Class A shares dropped more than 12% over two days, from approximately $32 per share on November 6, 2025, to about $28 per share by November 10, 2025 [1] - The stock continued to decline, reaching a low of $17 per share by November 21, 2025, representing a decrease of over 70% from the class period high of more than $57 per share [1]

Kyndryl Holdings, Inc. (KD) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP [Accessibility Statement] Skip NavigationDid you buy KD securities between August 7, 2024, and February 9, 2026?Affected Kyndryl Holdings, Inc. Investor Summary- Investor Action: Contact [Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)] for recovery options at no cost to investor- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the ...

PayPal Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before April 20, 2026 to Discuss Your Rights - PYPL [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PayPal Holdings, Inc. (NASDAQ: PYPL).Shareholders who purchased shares of PYPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is no ...

The Gross Law Firm Notifies REGENXBIO Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RGNX [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).Shareholders who purchased shares of RGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery ...

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for misrepresentation and failure to disclose critical information regarding its drug candidate for Huntington's Disease, potentially affecting investors who purchased shares during the specified period [1][5]. Group 1: Lawsuit Announcement - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of uniQure ordinary shares between September 24, 2025, and October 31, 2025 [1]. - Investors who purchased shares during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Legal Process and Participation - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][6]. - A lead plaintiff must be appointed by April 13, 2026, to represent the class in the litigation [1][3]. Group 3: Details of the Case - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - The claims suggest that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the truth was revealed [5]. Group 4: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].